We know that pDCs sense and process viral DNA through Toll-like receptor 9 (TLR9) and that IFN-β treatment of MS leads to a reduction in the activation of pDCs by viral pathogens and a decrease in the frequency of MS progression by inhibiting TLR9 processing (58). This evidence concerns the gene IFNB1 and myeloid sarcoma.